Topical Rofecoxib Solvent Systems for Reduced Cardiac Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Oral non-steroidal anti-inflammatory drugs (NSAIDs) like rofecoxib are associated with serious side effects, including cardiac toxicity, gastrointestinal issues, and cardiovascular events, necessitating the development of alternative formulations that effectively treat inflammation with reduced side effects.
Innovation Solution
Topical compositions containing rofecoxib dissolved in pharmaceutically acceptable solvent systems, such as isosorbide dimethyl ether and propylene carbonate, are developed to reduce systemic absorption and minimize cardiac toxicity, while maintaining therapeutic efficacy for pain and inflammation relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral rofecoxib formulations are used to treat inflammation and pain, then therapeutic efficacy is improved, but cardiac toxicity and cardiovascular events increase
Solution Approach 1:
The patent applies local quality by switching from systemic administration (oral) to localized administration (topical). The topical composition delivers rofecoxib directly to the site of inflammation through the skin, creating a local high concentration at the target site while maintaining low systemic concentrations, thereby preserving therapeutic efficacy at the application site while reducing cardiac toxicity associated with systemic exposure
Solution Approach 2:
The patent uses the skin and solvent system as an intermediary between the rofecoxib drug and the bloodstream. The specially formulated solvent system (containing compounds like isosorbide dimethyl ether and propylene carbonate) facilitates controlled delivery of rofecoxib through the skin barrier, allowing localized therapeutic action while acting as a buffer that prevents rapid systemic absorption and subsequent cardiac toxicity
2Object-affected harmful factors
If topical compositions are used to reduce systemic absorption, then cardiac toxicity is reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent applies parameter changes by carefully controlling the concentration of rofecoxib in the topical formulation and optimizing the composition of the solvent system. By adjusting these parameters, the formulation achieves sufficient local concentration at the application site to maintain therapeutic efficacy while limiting systemic absorption to levels that do not cause cardiac toxicity
Solution Approach 2:
The patent transitions from systemic circulation (one-dimensional blood distribution) to two-dimensional localized delivery through the skin. This dimensional change allows the drug to act locally at the site of inflammation without requiring high systemic concentrations, thereby maintaining efficacy while reducing the risk of cardiac toxicity associated with systemic exposure
3Reliability
If oral NSAIDs are administered to treat inflammation, then anti-inflammatory effects are achieved, but gastrointestinal side effects occur
Solution Approach 1:
The patent applies local quality by delivering the anti-inflammatory agent directly to the site of inflammation through topical application, bypassing the gastrointestinal tract entirely. This localized delivery method achieves therapeutic anti-inflammatory effects at the application site without exposing the gastrointestinal mucosa to the drug, thereby eliminating gastrointestinal bleeding as a side effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical rofecoxib compositions exhibit reduced cardiac toxicity and side effects compared to oral formulations, providing effective pain and inflammation relief with localized application, thereby addressing the limitations of oral NSAIDs.
Implementation Method 1
a therapeutically effective amount of rofecoxib dissolved in a solvent system comprising one or more pharmaceutically acceptable solvents
Data Source
AI summary
The present disclosure provides topical compositions of rofecoxib and methods of making said compositions. The present disclosure also provides methods of using topical compositions of rofecoxib to treat inflammation.